This company has shut down. Clade Therapeutics is no longer operating — its last tracked round was a Series A in 2021.
Explore the Startup GraveyardClade Therapeutics discovers and delivers next-generation cell medicines to improve the lives of patients.
Clade Therapeutics has raised $87.0M in total funding. The most recent round was Series A. The last funding was announced in November 2021.
Clade Therapeutics's investors include Bristol-Myers Squibb, Emerson Collective, LifeSci Venture Partners, Syncona Partners LLP.
Clade Therapeutics is headquartered in Cambridge, United States.
Clade Therapeutics discovers and delivers next-generation cell medicines to improve the lives of patients.
Clade Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Clade Therapeutics — Funding & Investors." VCBacked, November 3, 2021, https://www.vcbacked.co/company/clade-therapeutics. Accessed August 14, 2026.
VCBacked. (2021). Clade Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/clade-therapeutics
{{cite web |title=Clade Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/clade-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated